Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa

 Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment
                         of HIV/AIDS in South Africa

  PR Newswire


-- Builds on Existing South African Commercial Business

JOHANNESBURG and PITTSBURGH, Feb. 23, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq:
MYL), one of the world's leading generic and specialty pharmaceutical
companies, today announced that its subsidiary in South Africa, Mylan
(Proprietary) Limited, has launched a comprehensive portfolio of
antiretroviral (ARV) products. South Africa has the world's largest HIV/AIDS
population, with approximately 5.6 million[1] people living with the disease
and an estimated 1.7 million[2] people receiving treatment.

Mylan's South African ARV portfolio initially will consist of 11 first- and
second-line adult and pediatric regimens. Included are several innovative
products, such as fixed-dose combinations, single blister "co-packs,"
heat-stable products and novel pediatric formulations that have been approved
by the U.S. Food and Drug Administration (FDA) and the World Health
Organization (WHO).

Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's
7 billion people with access to high quality medicine. Recently, Mylan was
awarded a 19% share of the ARV tender conducted by the South African
government and we already have begun to deliver on this commitment. Building
on this, today we are pleased to launch a broad and innovative ARV portfolio
for the private sector. We believe that Mylan can set a new standard in the
treatment of HIV/AIDS in South Africa by providing health care providers and
those living with the disease access to high quality, affordable medicines."

Paul Miller, managing director and vice president of Mylan's South African
business noted, "Mylan is an established leader in ARVs, with a global
portfolio of 43 high quality ARVs, and the company has played a significant
role in reducing the cost of these important therapies. The launch of Mylan's
ARV portfolio in South Africa builds on our existing commercial presence in
the country and is consistent with the company's commitment to addressing
unmet needs with quality products. Mylan's ARV medicines are produced
according to current Good Manufacturing Practices at facilities that have been
inspected by leading regulatory authorities, including the South African
Medicines Control Council, FDA and WHO. These quality standards are paramount
everywhere that Mylan operates, including in South Africa."

Mylan has been a leading global player in the ARV arena for more than a
decade. In 2002, Mylan Laboratories Limited (formerly Matrix Laboratories
Limited) began providing reliable supplies of ARV active pharmaceutical
ingredients to generic drug makers. In 2007, the company began offering
finished dosage forms and launched a line of pediatric ARVs. Today, Mylan is
widely respected for the quality, dependability and affordability of its ARVs.
Mylan supplies ARVs to more than 120 countries around the world and nearly 40%
of HIV/AIDS patients receiving treatment in developing countries depend on one
of the company's ARV products.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit, do what's right, not what's easy
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which more than one-third of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside.



Contact: Media, Nina Devlin, +1-724-514-1968, or Investors, Kris King,
Press spacebar to pause and continue. Press esc to stop.